Moreover, 1 aa sequence shared by all liver transplantation patients and 2 aa sequences shared by at least two groups, which may serve as biomarkers to monitor the immune status of liver transplant patients.Ĭhronic hepatitis B virus (HBV) infection leads to a range of liver diseases with a series of symptoms. In addition, we found our results also show that various TRBV expression increased and some public sequences at different time points after liver transplantation, and the expression levels of 3 TRBV segments and 2 TRBJ segments were also significantly different in Pre, Post1, Post7 and NC groups. The Pre-group had more highly expanded T cell clones compared to Post1, Post7 and NC groups, and the diversity of the T cell repertoire of the Post7 group was significantly decreased compared to the Pre, Post1 and NC groups. We found that the TCR repertoire diversity of transplantation groups was relatively lower compared to NC group. We observed that the distributions of CDR3, VD indel, and DJ indel lengths were similar among the Pre, Post1, Post7 and NC groups. We sequenced the TCR β-chain complementary-determining region 3 (CDR3) repertoire in peripheral blood mononuclear cells (PBMCs) from 6 liver transplantation patients before transplantation (Pre) and on the first (Post1) and seventh days (Post7) after transplantation along with 6 NC. Here, we used high throughput immune repertoire sequencing technique to study the characteristics and diversity of the TCR repertoire between patients who underwent liver transplantation and healthy controls (NC). T lymphocyte cells recognise antigens, specifically by major histocompatibility complex (MHC), through a membrane protein T cell receptor (TCR). Liver cirrhosis of hepatitis B is an immune-related disease in which liver cells die during the body’s immune system activation to clear the virus, and the progress is closely related to T lymphocytes. Received: FebruAccepted: SeptemPublished: October 02, 2018 Keywords: T cell receptor immune repertoire next-generation sequencing liver transplantation *These authors contributed equally to this work ChinaĤThe Technology Company of iCarbonX, Shenzhen, Guangdong 518000, P.R. ChinaģThe Pingshan People’s Hospital of Shenzhen, Shenzhen, Guangdong 518118, P.R. ChinaĢClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen, Guangdong 518020, P.R. Guiqi Yang 1, *, Minglin Ou 1, 2, *, Huaizhou Chen 1, Changchun Guo 3, Jiejing Chen 1, Hua Lin 1, Donge Tang 2, Wen Xue 1, Wenlong Li 4, Weiguo Sui 1 and Yong Dai 2ġGuangxi Key Laboratory of Metabolic Diseases Research, Guilin 541002, P.R.
0 Comments
Leave a Reply. |